Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Adam Wolfe

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentRadiation Oncology, College of Medicine
DivisionRadiation Oncology Faculty
Address4104 Outpatient Circle
Mail Slot # 771
Little Rock AR 72205
Phone501-526-6813
ORCID ORCID Icon0000-0002-0123-7371 Additional info
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    P20GM152281     (MACNICOL, ANGUS)Mar 5, 2024 - Dec 31, 2028
    NIH/Nat. Inst. of General Medical Sciences
    Center for Molecular Interactions in Cancer (CMIC)
    Role: Principal Investigator
    1. ASTRO-CSDG-23-1037280-01-CDP     (Adam R. Wolfe)Jul 1, 2023 - Jun 30, 2027
    American Cancer Society
    Targeting the KRAS-USP7-RAD18 Axis to Overcome Radiation Resistance in Pancreatic Cancer
    Role: Principal Investigator
    ASTRO-CSDG     (WOLFE, ADAM)Jul 1, 2023 - Jun 30, 2027
    American Cancer Society, Inc.
    Targeting the KRAS-USP7-RAD18 Axis to Overcome Radiation Resistance in Pancreatic Cancer
    Role: Principal Investigator
    ASTRO-CSDG-23-1037280-01-CDP     (WOLFE, ADAM)Jul 1, 2023 - Jun 30, 2027
    American Cancer Society, Inc.
    Targeting the KRAS-USP7-RAD18 Axis to Overcome Radiation Resistance in Pancreatic Cancer
    Role: Principal Investigator
    KL2TR003108-03     (Adam R. Wolfe)Jul 1, 2021 - Jun 30, 2023
    NIH
    Targeting Homologous Repair to Overcome Genotoxic Therapy Resistance in Pancreatic Cancer
    Role Description: This project will generate a substantial amount of important pre-clinical data of a novel translational approach for studying resistant pancreatic cancer. Additionally, the KL2 award will provide the resources and foundation for my career as I transition into an early stage investigator in the field of Radiation Oncology.
    Role: Principle Investigator
         (Adam R. Wolfe)Apr 1, 2021 - Mar 31, 2023
    UAMS Team Science Award
    Synergizing methionine restriction with radiation therapy in KRAS mutant rectal cancer
    Role: Principle Investigator
    ROI630708     (Adam R. Wolfe)Jul 1, 2019 - Jun 30, 2021
    RADIATION ONCOLOGY INSTITUTE
    Development of a miRNA Signature to Personalize Radiation Therapy in PDAC
    Role: Principle Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Wolfe AR, Cui T, Baie S, Corrales-Guerrero S, Webb A, Castro-Aceituno V, Shyu DL, Karasinska JM, Topham JT, Renouf DJ, Schaeffer DF, Halloran M, Packard R, Robb R, Chen W, Denko N, Lisanti M, Thompson TC, Frank P, Williams TM. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Sci Adv. 2024 Mar; 10(9):eadj3551. PMID: 38427741.
      View in: PubMed
    2. Kaushik R, McCallin T, Sedillo DJ, Wolfe AD. Outcomes of a Peer Mentoring Circle: An Innovation to Improve Academic Physician Career Advancement in a Community Hospital Setting. Acad Med. 2023 02 01; 98(2):214-218. PMID: 36538672.
      View in: PubMed
    3. Zuniga O, Byrum S, Wolfe AR. Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq. Cancer Drug Resist. 2022; 5(4):926-938. PMID: 36627902.
      View in: PubMed
    4. Pillai R, Nugent K, Wolfe AD, Voeller J. Acute Right Arm Swelling in a 6-month-old Girl. Pediatr Rev. 2022 09 01; 43(9):517-520. PMID: 36045153.
      View in: PubMed
    5. Sebastian NT, Webb A, Merrell KW, Koay EJ, Wolfe AR, Zhang L, Wilhite TJ, Elganainy D, Robb R, Chen W, Cloyd J, Dillhoff M, Tsung A, Abushahin L, Noonan A, Williams TM. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021 Oct 15; 13(20). PMID: 34680317.
      View in: PubMed
    6. Wolfe AR, Chablani P, Siedow MR, Miller ED, Walston S, Kendra KL, Wuthrick E, Williams TM. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol. 2021 Sep 18; 16(1):181. PMID: 34537078.
      View in: PubMed
    7. Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021 07; 16(7):1086-1098. PMID: 33845212.
      View in: PubMed
    8. Wolfe AR, Siedow M, Nalin A, DiCostanzo D, Miller ED, Diaz DA, Arnett A, Cloyd JM, Dillhoff M, Ejaz A, Tsung A, Williams TM. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiother Oncol. 2021 05; 158:207-214. PMID: 33667588.
      View in: PubMed
    9. Wolfe AD, Bhalala U, Marshall V. Building a Local Research Symposium: The Crossroads of Scholarship, Education, and Faculty Development. MedEdPORTAL. 2020 12 24; 16:11048. PMID: 33409351.
      View in: PubMed
    10. Vazzano J, Frankel WL, Wolfe AR, Williams TM, Chen W. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems. Hum Pathol. 2021 03; 109:1-11. PMID: 33245985.
      View in: PubMed
    11. Wolfe AR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-Monserrate Z, Jacob JR, Palanichamy K, Chakravarti A, Williams TM. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2021 01 15; 27(2):554-565. PMID: 33087331.
      View in: PubMed
    12. Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Alexandra Diaz D, Miller ED, Chen W, Frankel WL, Noonan A, Williams TM. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med. 2020 07; 9(13):4711-4723. PMID: 32415696.
      View in: PubMed
    13. Wolfe AR, Wald P, Webb A, Sebastian N, Walston S, Robb R, Chen W, Vedaie M, Dillhoff M, Frankel WL, Kwon W, Jang JY, Williams TM. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Oncotarget. 2020 Mar 10; 11(10):913-923. PMID: 32206188.
      View in: PubMed
    14. Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. Int J Cancer. 2020 07 01; 147(1):107-115. PMID: 31609479.
      View in: PubMed
    15. Wolfe AR, Blakaj D, London N, Blakaj A, Klamer B, Pan J, Wakely P, Prevedello L, Bonomi M, Bhatt A, Raval R, Palmer J, Prevedello D, Gamez M, Carrau R. Erratum: Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience. J Neurol Surg B Skull Base. 2020 Jun; 81(3):e1. PMID: 37745951.
      View in: PubMed
    16. Wolfe AR, Blakaj D, London N, Blakaj A, Klamer B, Pan J, Wakely P, Prevedello L, Bonomi M, Bhatt A, Raval R, Palmer J, Prevedello D, Gamez M, Carrau R. Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience. J Neurol Surg B Skull Base. 2020 Jun; 81(3):287-294. PMID: 32500004.
      View in: PubMed
    17. Robb R, Yang L, Shen C, Wolfe AR, Webb A, Zhang X, Vedaie M, Saji M, Jhiang S, Ringel MD, Williams TM. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clin Cancer Res. 2019 08 01; 25(15):4749-4760. PMID: 31097454.
      View in: PubMed
    18. Wolfe AR, Grecula JC, Blakaj D, Wald P, Carlson M, Woods K, Dziedzic E, Vidrick A, Martin D, Shabsigh A. Robotic-assisted Intraoperative High-dose Rate Remote Brachytherapy Following Laparoscopic Robotic-assisted Resection of Pelvic Recurrence of Urethral Carcinoma. Adv Radiat Oncol. 2019 Jul-Sep; 4(3):443-446. PMID: 31360797.
      View in: PubMed
    19. Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM. Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report. Adv Radiat Oncol. 2019 Jan-Mar; 4(1):10-14. PMID: 30706003.
      View in: PubMed
    20. Wolfe AR, Williams TM. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Ann Pancreat Cancer. 2018 Aug; 1(8). PMID: 32656528.
      View in: PubMed
    21. Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, Zhang D, Horton J, Reuben JM, McMurray JS, Woodward WA. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):1034-1043. PMID: 29485045.
      View in: PubMed
    22. Stecklein SR, Reddy JP, Wolfe AR, Lopez MS, Fouad TM, Debeb BG, Ueno NT, Brewster AM, Woodward WA. Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. J Cancer. 2017; 8(10):1726-1732. PMID: 28819368.
      View in: PubMed
    23. Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 2016 Dec 13; 7(50):82482-82492. PMID: 27756885.
      View in: PubMed
    24. Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39. PMID: 27078845.
      View in: PubMed
    25. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8). PMID: 27075851.
      View in: PubMed
    26. Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA. MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in?Breast Cancer. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):791-9. PMID: 27055396.
      View in: PubMed
    27. Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat. 2015 Dec; 154(3):495-508. PMID: 26590814.
      View in: PubMed
    28. Wolfe AR, Woodward WA. Breast Cancer Stem Cell Correlates as Predicative Factors for Radiation Therapy. Semin Radiat Oncol. 2015 Oct; 25(4):251-9. PMID: 26384273.
      View in: PubMed
    29. Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT, Woodward WA. High-density and very-low-density lipoprotein?have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2015 Apr 01; 91(5):1072-80. PMID: 25832697.
      View in: PubMed
    30. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189. PMID: 23300537.
      View in: PubMed
    Wolfe's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (161) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (29) people
    _
    Same Department Expand Description
    Search Department